Long non-coding RNAs and nuclear factor-B crosstalk in cancer and other human diseases
Publication date: Available online 19 October 2019Source: Biochimica et Biophysica Acta (BBA) - Reviews on CancerAuthor(s): Subash C. Gupta, Nikee Awasthee, Vipin Rai, Srinivas Chava, Venugopal Gunda, Kishore B. ChallagundlaAbstractThe regulation of the pleiotropic transcription factor, nuclear factor-κB (NF-κB) by miRNAs and proteins is extensively studied. More recently, the NF-κB signaling was also reported to be regulated by several long non-coding RNAs (lncRNAs) that constitute the major portion of the noncoding component of the human genome. The common NF-κB associated lncRNAs include NKILA, HOTAIR, MALAT1, ANRIL, Lethe, MIR31HG, and PACER. The lncRNA and NF-κB signaling crosstalk during cancer and other diseases such as cardiomyopathy, celiac disease, cerebral infarction, chronic kidney disease, diabetes mellitus, Kawasaki disease, pregnancy loss, and rheumatoid arthritis. Some NF-κB related lncRNAs can affect gene expression without modulating NF-κB signaling. Most of the lncRNAs with a potential to modulate NF-κB signaling are regulated by NF-κB itself suggesting a feedback regulation. The discovery of lncRNAs have provided a new type of regulation for the NF-κB signaling and thus could be explored for therapeutic interventions. The manner in which lncRNA and NF-κB crosstalk affects human pathophysiology is discussed in this review. The challenges associated with the therapeutic interventions of this c...
[Observer] -An evolving era for Sub-Saharan Africa
TYPE 2 diabetes is a common condition which affects a person ’s blood sugar level control, and left untreated, serious health complications can occur. One way to control blood sugar levels could be to eat a vegetable native to the Mediterranean.
Although 1 in 200 women with fertility issues have overt thyroid dysfunction and many more subclinical hypothyroidism, it is unclear how best to identify or manage them, say UK researchers.Medscape News UK
A Holyrood committee finds 18% of cancer patients in June were not seen within the six-week target.
[allAfrica] Nairobi -AllAfrica.com's Bacary Dabo spoke with Plan International's CEO Anne-Birgitte Albrectsen, while attending the International Conference on Population and Development (ICPD25) in Nairobi, Kenya.
ConclusionsThe effect of therapy directed toward EGFR mutation or EML4 –ALK fusion gene might obscure the significant prognostic difference between M1b and M1c.
ConclusionApalutamide had manageable safety profile, without any DLT or any new safety signals, and favourable efficacy in Japanese mCRPC patients. Thus, it was ascertained to be an adequate dosage regimen in Japanese mCRPC patients.Trial registrationClinicalTrials.gov identifier: NCT02162836.
Attack on cancer drug comes amid near-halving in sector value since last year
Roche today announced that results from a number of studies from across its growing breast cancer portfolio will be presented at the San Antonio Breast Cancer Symposium (SABCS), from 10-14 December 2019.